Core Scientific, Inc./tx 8-K

What Happened
Core Scientific, Inc. announced an amendment to its Delayed-Draw Bridge Credit Agreement and increased its term loan commitments by $500.0 million through the accordion feature of the existing credit agreement. On March 18, 2026 (the “Closing Date”), the Company entered into Amendment No. 1 with Morgan Stanley Senior Funding, Inc. (administrative and collateral agent) and JPMorgan Chase Bank, N.A. (amendment no. 1 term lender) and borrowed the full $500.0 million on the Closing Date. The amendment raises total term loan commitments to $1.0 billion.

Key Details

• Amendment No. 1 executed March 18, 2026; press release issued March 23, 2026.
• Incremental commitment: $500.0 million; total term loan commitments after amendment: $1.0 billion.
• Lenders/agents: Morgan Stanley Senior Funding, Inc. (agent) and JPMorgan Chase Bank, N.A. (term lender).
• The Company borrowed the full $500.0 million on the Closing Date.

Why It Matters
This filing documents a material debt financing transaction: Core Scientific increased its term loan capacity and immediately drew the incremental $500M, which changes the company’s funded debt profile. Investors should note this is additional borrowed capital (not equity) and that the Company publicly disclosed the amendment and borrowing in a March 23, 2026 press release filed as an exhibit to the 8‑K.